Project Grant R01CA301386
Award Date
4/1/25
Completion Date
3/31/30
Dollars Obligated
$667K
Federal Agency
National Cancer Institute
Federal Grant Program
93.396
Assistance Type
Project Grant
Place of Performance
San Francisco, CA 94143, USA
Similar Awards
This federal Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) provides $622,984 to the University of California, Los Angeles (UCLA) to conduct a multi-year systems metabolic approach for characterizing and imaging pancreatic cancer phenotypes. The key objectives are to:
Integrate multi-scale measurements from cell, tissue, and organ levels with advanced imaging modalities (PET/CT) to establish definitive phenotypes of pancreatic...
This federal Project Grant award of $436,431 from the National Cancer Institute's Cancer Biology Research program (CFDA 93.396) supports research to target metabolic crosstalk in pancreatic ductal adenocarcinoma (PDA). The University of California, Irvine is the prime awardee, conducting fundamental investigations into mechanisms that maintain cancer cell heterogeneity and metabolic symbiosis in PDA tumors. The research aims to identify oncogenic and stress pathways that can be targeted to...
This five-year, $354,563 Project Grant from the National Cancer Institute's Cancer Biology Research program (CFDA 93.396) supports research to dissect the roles of Lunatic Fringe (LFNG)-dependent Notch signaling in the development and progression of pancreatic cancer. The award was made to the University of Mississippi Medical Center (UMMC) on May 1, 2024.
The research aims to: 1) Determine the roles of LFNG-dependent Notch signaling in pancreatic cancer development from LFNG-expressing...
This $578,998 Project Grant award from the National Cancer Institute (under CFDA 93.395 - Cancer Treatment Research) aims to develop a novel targeted therapeutic strategy against metastatic pancreatic ductal adenocarcinoma (PDAC). The key objectives are to:
Determine the mechanisms by which the cancer-specific Tn antigen enhances PDAC tumor progression and identify Tn-expressing glycoproteins through advanced glycoproteomics analysis in mouse models and clinical samples.
Validate the role...
This Project Grant award from the National Cancer Institute (CFDA 93.396 Cancer Biology Research) provides $485,558 over 5 years to The General Hospital Corporation (Massachusetts General Hospital) for a study on a novel glutathione-dependent metabolic pathway that drives metastatic outgrowth in pancreatic cancer. The research aims to molecularly characterize key factors involved in this pathway, with the potential to develop new diagnostic markers and therapeutic strategies for treating...
This Project Grant award from the National Cancer Institute's Cancer Biology Research program (CFDA 93.396) provides $616,495 to the University of Texas MD Anderson Cancer Center to conduct research on the role of sulfatide metabolism in the development and progression of pancreatic cancer precursor lesions. The key objectives are: 1) defining the biological functions of sulfatides in pancreatic cancer precursor lesions, 2) testing whether inhibiting sulfatide metabolism is a viable cancer...
This federal Project Grant award, provided by the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395), is focused on the development of a theragnostic radiopharmaceutical for the treatment of pancreatic cancer. The key products and services to be delivered include:
The project aims to identify and optimize peptide ligands that target the claudin-4 (CLDN4) protein, which is overexpressed in pancreatic adenocarcinoma. These peptides will be evaluated for...
This Cooperative Agreement award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) provides $1,615,866 in funding to The Regents of the University of California, San Francisco (UCSF) to develop and validate a two-tier classifier for identifying advanced neoplasia in pancreatic cystic lesions. The project aims to refine target proteins and proteomics-based biomarkers to improve the detection and diagnosis of high-grade dysplasia or invasive pancreatic...
This $125,000 Project Grant award from the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training program (CFDA 93.859) supports research to investigate the role of cellular metabolism in regulating precancerous stages of pancreatic cancer development.
The key products and services to be delivered through this 2-year grant include: 1) Mechanistic studies on how the metabolic enzyme ME1 contributes to acinar-to-ductal metaplasia (ADM) and...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $686,979.00 in funding to The Regents of the University of California, San Francisco (UCSF) to conduct research aimed at understanding and disrupting tumor metabolism and enhancing anti-tumor immunity in diffuse midline gliomas (DMGs), a type of aggressive pediatric brain cancer. The key goals are to: 1) Delineate how the H3K27M mutation in DMGs upregulates the glycolytic enzyme PGK1...